开云app官网登录入口网页版-官方正版

#吡非尼酮#

17篇内容 | 1399人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2159522, encodeId=6eb021595224e, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>与吸入<a href='/topic/show?id=189a124523a' target=_blank style='color:#2F92EE;'>#N-乙酰半胱氨酸#</a>联合治疗<a href='/topic/show?id=18476e89768' target=_blank style='color:#2F92EE;'>#特发性肺纤维化#</a>疗效, objectTitle=Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效, objectType=article, longId=198000, objectId=ff2a19800082, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020724/1595573432196_1739456.jpg, objectUrl=/article/show_article.do?id=ff2a19800082, replyNumber=0, likeNumber=87, createdTime=2023-09-25, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ff2a19800082, moduleTitle=Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ff2a19800082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2129637, encodeId=d86f212963e59, content=男性短寿竟是因为<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>正在丢失！男性Y染色体会出现丢失现象，这种丢失是导致男性罹患<a href='/topic/show?id=92f410608421' target=_blank style='color:#2F92EE;'>#心肌疤痕#</a>和<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>等<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病，进而致其过早死亡的关键因素，<a href='/topic/show?id=4c239032154' target=_blank style='color:#2F92EE;'>#衰老#</a>，也许几千年以后，地球上将不再有Y染色体，以及一条X是男性，两条XX<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>是女性，确实有这样的可能。<a href='/topic/show?id=18476e89768' target=_blank style='color:#2F92EE;'>#特发性肺纤维化#</a>的<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>，这些药物可能很难缓解。, objectTitle=Science：男性短寿竟是因为Y染色体正在丢失！, objectType=article, longId=732846, objectId=d2a8e32846f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220720/1658249781404_5295905.jpg, objectUrl=/article/show_article.do?id=d2a8e32846f2, replyNumber=0, likeNumber=138, createdTime=2023-05-02, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d2a8e32846f2, moduleTitle=Science：男性短寿竟是因为Y染色体正在丢失！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d2a8e32846f2)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2118585, encodeId=fa85211858525, content=<a href='/topic/show?id=7d71822e3e5' target=_blank style='color:#2F92EE;'>#肺纤维化#</a><a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a> <a href='/topic/show?id=23ec4e37786' target=_blank style='color:#2F92EE;'>#尼达尼布#</a>, objectTitle=综述：特发性肺纤维化治疗药物治疗进展, objectType=article, longId=216060, objectId=d14f21606025, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20210819/432253f6fe8b4ccf8ed27604419d1b28.jpg, objectUrl=/article/show_article.do?id=d14f21606025, replyNumber=0, likeNumber=110, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d14f21606025, moduleTitle=综述：特发性肺纤维化治疗药物治疗进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d14f21606025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636403, encodeId=541b1636403a3, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=吡非尼酮胶囊在中国肺纤维化人群中的耐受性研究, objectType=article, longId=732522, objectId=f8cae3252216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8cae3252216, replyNumber=0, likeNumber=111, createdTime=2023-06-15, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8cae3252216, moduleTitle=吡非尼酮胶囊在中国肺纤维化人群中的耐受性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f8cae3252216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636402, encodeId=91671636402cf, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Lancet Respir Med：西地那非与吡非尼酮对特发性纤维化相关的肺动脉高压患者中的疗效和安全性评估, objectType=article, longId=217949, objectId=9c9021e94927, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c9021e94927, replyNumber=0, likeNumber=84, createdTime=2022-01-20, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c9021e94927, moduleTitle=Lancet Respir Med：西地那非与吡非尼酮对特发性纤维化相关的肺动脉高压患者中的疗效和安全性评估, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9c9021e94927)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636400, encodeId=3dc716364005c, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Respirology：尼达尼布或吡非尼酮治疗可使晚期特发性肺纤维化FVC保持稳定, objectType=article, longId=214896, objectId=7d37214896b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d37214896b1, replyNumber=0, likeNumber=94, createdTime=2021-10-05, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d37214896b1, moduleTitle=Respirology：尼达尼布或吡非尼酮治疗可使晚期特发性肺纤维化FVC保持稳定, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7d37214896b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636401, encodeId=68fa163640154, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Nat Med：吡非尼酮治疗射血分数正常的心衰效果如何？, objectType=article, longId=215715, objectId=62a4215e15fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62a4215e15fa, replyNumber=0, likeNumber=104, createdTime=2022-06-25, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62a4215e15fa, moduleTitle=Nat Med：吡非尼酮治疗射血分数正常的心衰效果如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=62a4215e15fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636399, encodeId=91d11636399b8, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Lancet Respirat Med：吡非尼酮或可缓解除了IPF以外的纤维化ILD的病情进展, objectType=article, longId=209630, objectId=b1b2209630f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b2209630f3, replyNumber=0, likeNumber=105, createdTime=2022-02-09, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b2209630f3, moduleTitle=Lancet Respirat Med：吡非尼酮或可缓解除了IPF以外的纤维化ILD的病情进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b1b2209630f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636398, encodeId=e3361636398d6, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Lancet respirat med：吡非尼酮加用西地那非对晚期特发性肺纤维化无治疗益处, objectType=article, longId=199740, objectId=6779199e407c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6779199e407c, replyNumber=0, likeNumber=88, createdTime=2020-09-09, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6779199e407c, moduleTitle=Lancet respirat med：吡非尼酮加用西地那非对晚期特发性肺纤维化无治疗益处, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6779199e407c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636397, encodeId=e3a8163639eaf, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效, objectType=article, longId=198000, objectId=ff2a19800082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff2a19800082, replyNumber=0, likeNumber=95, createdTime=2021-01-04, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff2a19800082, moduleTitle=Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ff2a19800082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636396, encodeId=1d1916363969b, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Eur Respir J：尼达尼布与吡非尼酮联合治疗特发性肺纤维化的安全性分析, objectType=article, longId=145895, objectId=06b8145895d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06b8145895d8, replyNumber=0, likeNumber=102, createdTime=2019-07-14, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06b8145895d8, moduleTitle=Eur Respir J：尼达尼布与吡非尼酮联合治疗特发性肺纤维化的安全性分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=06b8145895d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636395, encodeId=b1a71636395da, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Lancet respir med：CCL18是更有效的特发性肺纤维化及吡非尼酮治疗进展预测标志物, objectType=article, longId=142133, objectId=221d14213306, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=221d14213306, replyNumber=0, likeNumber=86, createdTime=2019-05-14, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=221d14213306, moduleTitle=Lancet respir med：CCL18是更有效的特发性肺纤维化及吡非尼酮治疗进展预测标志物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=221d14213306)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636393, encodeId=951a1636393b2, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Respir Med：吡非尼酮治疗特发性肺纤维化急性加重是否有效？, objectType=article, longId=102487, objectId=a2c710248ebf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c710248ebf, replyNumber=0, likeNumber=85, createdTime=2017-09-17, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c710248ebf, moduleTitle=Respir Med：吡非尼酮治疗特发性肺纤维化急性加重是否有效？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a2c710248ebf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636391, encodeId=95bf1636391ac, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Blood：吡非尼酮具有治疗cGVHD引起的闭塞性细支气管炎的潜力, objectType=article, longId=98029, objectId=a24c980292e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a24c980292e, replyNumber=0, likeNumber=80, createdTime=2018-01-15, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a24c980292e, moduleTitle=Blood：吡非尼酮具有治疗cGVHD引起的闭塞性细支气管炎的潜力, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a24c980292e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636394, encodeId=4bf1163639498, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Respirology：吡非尼酮和尼达尼布治疗肺纤维化：耐受性和不良药物反应, objectType=article, longId=113201, objectId=c5d91132012a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5d91132012a, replyNumber=0, likeNumber=98, createdTime=2018-06-26, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5d91132012a, moduleTitle=Respirology：吡非尼酮和尼达尼布治疗肺纤维化：耐受性和不良药物反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c5d91132012a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636392, encodeId=08b21636392fd, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=Am J Resp Crit Care：吡非尼酮减少特发性肺纤维化患者呼吸相关的住院！, objectType=article, longId=98052, objectId=5a18980523a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a18980523a, replyNumber=0, likeNumber=86, createdTime=2017-12-28, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a18980523a, moduleTitle=Am J Resp Crit Care：吡非尼酮减少特发性肺纤维化患者呼吸相关的住院！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5a18980523a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636390, encodeId=c9f81636390f4, content=<a href='/topic/show?id=ab5b3918830' target=_blank style='color:#2F92EE;'>#吡非尼酮#</a>, objectTitle=FDA授予GP-101（吡非尼酮气雾剂）孤儿药地位, objectType=article, longId=38941, objectId=c5e43894160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e43894160, replyNumber=0, likeNumber=111, createdTime=2014-11-02, rootId=0, userName=1249898am22暂无昵称, userId=8aba22623857, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e43894160, moduleTitle=FDA授予GP-101（吡非尼酮气雾剂）孤儿药地位, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c5e43894160)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

吡非尼酮

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#吡非尼酮#与吸入#N-乙酰半胱氨酸#联合治疗#特发性肺纤维化#疗效

Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效

2023-09-25发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起男性短寿竟是因为#Y染色体#正在丢失！男性Y染色体会出现丢失现象，这种丢失是导致男性罹患#心肌疤痕#和#心力衰竭#等#心血管#疾病，进而致其过早死亡的关键因素，#衰老#，也许几千年以后，地球上将不再有Y染色体，以及一条X是男性，两条XX#染色体#是女性，确实有这样的可能。#特发性肺纤维化#的#吡非尼酮#，这些药物可能很难缓解。

Science：男性短寿竟是因为Y染色体正在丢失！

2023-05-02发表于上海

showtest (审核中...)

前往app查看评论内容

#肺纤维化##吡非尼酮# #尼达尼布#

综述：特发性肺纤维化治疗药物治疗进展

2023-03-10发表于上海

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

吡非尼酮胶囊在中国肺纤维化人群中的耐受性研究

2023-06-15

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Lancet Respir Med：西地那非与吡非尼酮对特发性纤维化相关的肺动脉高压患者中的疗效和安全性评估

2022-01-20

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Respirology：尼达尼布或吡非尼酮治疗可使晚期特发性肺纤维化FVC保持稳定

2021-10-05

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Nat Med：吡非尼酮治疗射血分数正常的心衰效果如何？

2022-06-25

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Lancet Respirat Med：吡非尼酮或可缓解除了IPF以外的纤维化ILD的病情进展

2022-02-09

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Lancet respirat med：吡非尼酮加用西地那非对晚期特发性肺纤维化无治疗益处

2020-09-09

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效

2021-01-04

智者为医08 (审核中...)

前往app查看评论内容

#吡非尼酮#

Eur Respir J：尼达尼布与吡非尼酮联合治疗特发性肺纤维化的安全性分析

2019-07-14

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Lancet respir med：CCL18是更有效的特发性肺纤维化及吡非尼酮治疗进展预测标志物

2019-05-14

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Respir Med：吡非尼酮治疗特发性肺纤维化急性加重是否有效？

2017-09-17

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Blood：吡非尼酮具有治疗cGVHD引起的闭塞性细支气管炎的潜力

2018-01-15

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Respirology：吡非尼酮和尼达尼布治疗肺纤维化：耐受性和不良药物反应

2018-06-26

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

Am J Resp Crit Care：吡非尼酮减少特发性肺纤维化患者呼吸相关的住院！

2017-12-28

1249898am22暂无昵称 (审核中...)

前往app查看评论内容

#吡非尼酮#

FDA授予GP-101（吡非尼酮气雾剂）孤儿药地位

2014-11-02

科室
- - 订阅+
  - 更多科室
工具
服务